Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years (CROSBI ID 573168)
Prilog sa skupa u zborniku | sažetak izlaganja sa skupa
Podaci o odgovornosti
Pavićević, Radomir ; Bialk, Peter ; Bubanović, Gordana ; Krajna, Ana ; Samaržija, Miroslav ; Pavićević, Lukrecija
engleski
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years
The clinical application of cytokeratin marker CYFRA 21-1 was standardized on 2000 patients. In all patients the star value of CYFRA 21-1 was determined before therapy (Roche Diagnoastics). Tumor marker CYFRA 21-1 was ssessed longitudinally 1 to 24 months after the therapy, or before the next therapy. On eto three months after the surgical treatment in 87% of the patients the marker values decreased to the healthy population level...
CYFRA 21-1; NSCLC; tumor marker
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
2001.
objavljeno
Podaci o matičnoj publikaciji
Podaci o skupu
Cambridge Healthtech Institute's fifth annual «Gene Funcional analysis: Genome 2001» tri-conference
poster
08.03.2001-09.03.2001
San Francisco (CA), Sjedinjene Američke Države
